research
support
information
campaigning
health professionals
education
recent research
• archive Sept 2008
• archive August 2008
• archive July 2008
links
news
get involved
news
who we are
what we do
how you can help
contact us
make a donation
message board
work for us
large print version
printable version

Recent research

We have collated a selection of the latest research articles to help you keep up to date with developments in the field of prostate cancer. This page directs you to the abstracts of articles that have been published in the medical journals over the last few weeks. Check back each month for an updated list.

The following articles have been selected for their currency, relevance to UK clinical practice and general interest. The full text may be obtained from your Trust’s library service or via ATHENS registration.

Archive - Research articles published July 2008

View articles on:

• Risk
• Genetics
• Diet
• BPH
• Diagnosis
• Treatment
• Side effects
• Quality of life
• Communication
• General cancer
• Patient experience
• Psychology
• Complementary therapy
• Advanced disease
• Survival

Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Leitzmann MF, Ahn J, Albanes D et al.
Cancer Causes Control; advanced online publication (July 2008).

Lower urinary tract symptoms and risk of prostate cancer: The HUNT 2 Cohort, Norway.
Martin RM, Vatten L, Gunnell D et al.
Int J Cancer; advanced online publication (July 2008).

Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study.
Kakizaki M, Inoue K, Kuriyama S et al.
Br J Cancer 2008; 99:176-178.

Issues faced by unaffected men with a family history of prostate cancer: a multidisciplinary overview.
Wakefield CE, Meiser B, Gaff CL et al.
J Urol 2008; 180(1):38-46.

Differential gene expression in the peripheral zone compared to the transition zone of the human prostate gland.
Noel EE, Ragavan N, Walsh MJ et al.
Prostate Cancer Prostatic Dis 2008; 11:173-180.

Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort.
Mucci LA, Pawitan Y, Demichelis F et al.
Cancer Epidemiol Biomarkers Prev. 2008;17(7):1682-8.

Dairy products, dietary calcium and vitamin d intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies.
Huncharek M, Muscat J, and Kupelnick B.
Nutr Cancer 2008; 60(4): 421-41.

Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate.
Traka M, Gasper AV, Melchini A et al
PLoS ONE. 2008;3(7):e2568

Conformity to traditional Mediterranean diet and cancer incidence: the Greek EPIC cohort.
Benetou V, Trichopoulou A, Orfanos P et al.
Br J Cancer. 2008;99(1):191-5.

Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials.
Lourenco T, Pickard R, Vale L et al.
BMJ 2008; 337:a449.

Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
Hong SK, Han BK, Chung JS et al.
BJU Int; advanced online publication (July 2008).

Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer.
Desouza NM, Riches SF, Vanas NJ et al.
Clin Radiol 2008; 63(7): 774-82.

Serum markers for prostate cancer: a rational approach to the literature.
Steuber T, O'Brien MF, Lilja H.
Eur Urol 2008; 54(1):31-40.

PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging.
Loeb S, Kettermann A, Ferrucci L et al.
Eur Urol; advanced online publication (July 2008).

Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature.
Shariat SF, Karakiewicz PI, Suardi N et al.
Clin. Cancer Res. 2008; 14:4400-4407.

Analysis of T1c Prostate Cancers Treated at Very Low Prostate-Specific Antigen Levels.
Stephenson AJ, Jones JS, Hernandez AV et al.
Eur Urol; advanced online publication (July 2008).

Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer.
Lu-Yao GL, Albertsen PC, Moore DF et al.
JAMA 2008;300(2):173-181.

Robotic prostatectomy: a review of outcomes compared with laparoscopic and open approaches.
Berryhill R Jr, Jhaveri J, Yadav R et al.
Urology 2008; 72(1):15-23.

Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U, Scattoni V, Freschi M et al.
Eur Urol 2008; 54(1):118-25.

Accuracy of life tables in predicting overall survival in patients after radical prostatectomy.
Walz J, Suardi N, Shariat SF et al.
BJU Int 2008;102(1):33-8.

Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men.
Jeldres C, Suardi N, Walz J et al.
Eur Urol 2008; 54(1):107-16.

Impact of nerve sparing on surgical margins and biochemical recurrence: results from the SEARCH database.
Nelles JL, Freedland SJ, Presti JC Jr et al.
Prostate Cancer Prostatic Dis; advanced online publication (July 2008).

Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.
Hernandez DJ, Nielsen ME, Han M et al.
Urology. 2008;72(1):172-6.

Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy.
Loeb S, Roehl KA, Viprakasit DP et al.
Eur Urol. 2008; 54(1):88-94.

A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer.
Trabulsi EJ, Valicenti RK, Hanlon AL et al.
Urology; advanced online publication (July 2008).

Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ, Malcolm JB, Derweesh IH et al.
BJU Int. 2008;102(1):39-43.

Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
Morales A, Black AM, Emerson LE.
BJU Int; advanced online publication (July 2008).

Cognitive effects of hormone therapy in men with prostate cancer: a Review.
Nelson CJ, Lee JS, Gamboa MC et al.
Cancer; advanced online publication (July 2008).

Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA, Spry NA, Taaffe DR et al.
BJU Int 2008;102(1):44-7.

Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, one year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDRBT).
Joseph KJ, Alvi R, Skarsgard D et al.
Radiat Oncol. 2008; 3:20.

Implementing an informed decision-making programme for urology patients
Garden J.
Journal of Communication in Healthcare;1(3): 297-310
Visit the publisher’s website www.henrystewart.com

Presence, communication and treatment of fatigue and pain complaints in incurable cancer patients.
Collins S, de Vogel-Voogt E, Visser A et al.
Patient Educ Couns. 2008;72(1):102-8.

Treatment of depression in patients with cancer.
Rodin G.
Lancet. 2008; 372(9632):8-10.

Prostate cancer in London: is the triadic clinical encounter the standard?
Hughes AE and Leary A.
International Journal of Urological Nursing 2008; 2(2):51-54.
Visit the publisher’s website www3.interscience.wiley.com

Understanding the causes of depression among prostate cancer patients: development of the effects of prostate cancer on lifestyle questionnaire.
Sharpley CF, Bitsika V, Christie DR.
Psychooncology.; advanced online publication (July 2008).

Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer.
Cherrier MM, Aubin S, Higano CS.
Psychooncology.; advanced online publication (July 2008).

An Object Lesson: Source Determines the Relations That Trait Anxiety, Prostate Cancer Worry, and Screening Fear Hold with Prostate Screening Frequency.
Consedine NS, Adjei BA, Ramirez PM et al.
Cancer Epidemiol. Biomarkers Prev. 2008; 17:1631-1639.

The use of complementary therapy by men with prostate cancer in the UK.
Wilkinson S, Farrelly S, Low J et al.
Eur J Cancer Care (Engl); advanced online publication (July 2008).

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven.
Attard G, Reid AH, Yap TA et al.
J Clin Oncol.; advanced online publication (July 2008).

PSA Kinetics Provide Improved Prediction of Survival in Metastatic Hormone-Refractory Prostate Cancer.
Robinson D, Sandblom G, Johansson R et al.
Urology; advanced online publication (July 2008).

The postchemotherapy PSA surge syndrome.
Thuret R, Massard C, Gross-Goupil M et al.
Ann Oncol. 2008;19(7):1308-11.

Cancer survival in five continents: a worldwide population-based study (CONCORD).
Coleman MP, Quaresma M, Berrino F et al.
Lancet Oncol; advanced online publication (July 2008).